Future directions in the treatment of androgen-independent prostate cancer (Q36153508)

12 August 2017

1 reference

title

Future directions in the treatment of androgen-independent prostate cancer (English)

1 reference

12 August 2017

1 reference

Daniel P Petrylak

1

1 reference

PubMed ID

15939077

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

65

1 reference

12 August 2017

6 Suppl

1 reference

12 August 2017

8-12

1 reference

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

An interdisciplinary approach to treating prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.04.020

10.1016/J.UROLOGY.2005.04.020

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15939077